Case Report
Effective Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease by B-Cell Targeted Therapy with Rituximab
Table 1
Development of laboratory and clinical parameters in response to different immunosupressive agents.
| | Parameter |
Treatment | MTX + prednisolone
(baseline) | Cyclophophamide + prednisolone
(week 18) | Rituximab + MTX + prednisolone
(week 59) |
| | 6MWT (% of debit) | 380 m (63.60%) | 436 m (79.39%) | 536 m (90.44%) | | FVC (% of debit) | 2.49 L (56.8%) | 3.36 L (76%) | 3.49 L (87%) | | BGA | | | | | pO2 | 53 mmHg | 62 mmHg | 63 mmHg | | pCO2 | 35 mmHg | 38 mmHg | 36 mmHg | | DAS 28 | 7.47 | 7.7 | 2.8 | | CRP | 131 mg/L | 72 mg/L | 1.7 mg/L | Ultrasound synovitis
Score (PIP II–V) | 10 | 7 | 4 |
|
|
